Q2 2026 delivered 8% organic revenue growth, led by U.S. pet health and innovation products like Zenrelia and Credelio Quattro. Guidance for revenue, EBITDA, and EPS was raised, with margin expansion and reduced leverage. The business remains well-positioned for continued growth.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.